Targeted Disruption of the JAK2/STAT3 Pathway in Combination with Systemic Administration of Paclitaxel Inhibits the Priming of Ovarian Cancer Stem Cells Leading to a Reduced Tumor Burden

Khalid Abubaker(St Vincent's Hospital), Nuzhat Ahmed(The University of Melbourne)
Frontiers in Oncology
April 9, 2014
Cited by 9


Related Papers